ANGPT2 and cancer: AMG-386 is a small peptibody against the TIE2 ligands ANGPT1 and ANGPT2, and its efficacy is currently tested against different types of cancer, including BCa, in phase 1 and 2, clinical trials (NCT00511459, NCT00807859, and NCT01042379) [51].